Wayne, PA – According to filings with the U.S. Securities and Exchange Commission, Palvella Therapeutics is raising $45,000,002.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Wes Kaupinen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Palvella Therapeutics

Derived from the Finnish word for to serve, Palvella Therapeutics was founded with the single-minded goal of serving individuals suffering from serious rare genetic diseases with no approved treatments. By developing pathogenetically targeted therapies that address the root causes of these diseases, we believe we can dramatically enhance quality of life.

To learn more about Palvella Therapeutics, visit http://www.palvellatx.com/

Contact:
Wes Kaupinen, President and Chief Executive Officer
484-253-1461
wes@palvellatx.com
https://www.linkedin.com/in/wes-kaupinen-0090334b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved